207940 · SAMSUNG BIOLOGICS Co., Ltd.

1219000.00

KRW

-58000.00 (-4.542%)

08/10/2026 12:00:00 AM

Price change (7D)

Unlock stock Insights

Create a free account to unlock price targets, recommendations, and commentary.

Overview

Market Cap

KRW61.44T

63.70

EV/EBITDA

41.8

DIV Yield

0%

Payout Ratio

0%

MQV Rating

4Weak

As at 08/10/2026 12:00:00 AM

Price Chart

Description

SAMSUNG BIOLOGICS Co., Ltd. engages in the provision of contract development and manufacturing organization (CDMO) services for pharmaceutical products. It operates through the CDMO and Biopharmaceutical Development and Commercialization business divisions. The CDMO division provides development services from cell line development to early clinical trials, including cell line development, processes, formulations, and analysis methods. The Biopharmaceutical Development and Commercialization division focuses on the development and commercialization of biosimilars and is conducting research and development on various disease fields such as autoimmune diseases, cancer diseases, ophthalmic diseases, and blood diseases. The company was founded on April 22, 2011 and is headquartered in Incheon, South Korea.

All-Companies
All-Consensus
Consensus Cheap
HALO 100
HALO 200
HALO All
HALO Capital Efficiency
Short Term Trend - Short

Key Fundamentals

EPS 3 yr Growth

50.30%

EBITDA Margin

59.30%

Operating Cashflow

₩2,247,807m

Free Cash Flow Return

22.50%

ROIC

16.20%

Interest Coverage

92.70

Quick Ratio

0.90

Performance

52 weeks range

Low 1219719.62 - 1973601.62

Trade Value (12mth)

US$16,180,237.00

1 week

-7.17%

1 month

-11.15%

YTD

-23.61%

1 year

-12.73%

All time high

1973600.00

Additional Data

Shares Outstanding (Fully Diluted)

47m

HALO Sector

Healthcare

Next Company Report Date

27-Jan-27

Next Ex Dividend Date

N/A

Next Dividend Pay Date

N/A

Reporting Currency

KRW

Short Sell (% of issue)

0.00

Consensus

Unlock full consensus

Consensus score

/10

Recommendation

Buy

Target price

Deviation

Health Scores

Short Term

Mean Reversion

Neutral

Trend

Very Weak

Event

Neutral

Halo Model

Mqv

Weak

Garp

Neutral

Mqv Small

Neutral

Momentum

Price

Very Weak

Earnings

Very Weak

Growth

Earnings

Neutral

Dividends

Very Weak

Quality

Capital Efficiency

Very Strong

Balance Sheet

Neutral

Valuation

Unlock full dataset

Value

Consensus

Yield

News & Announcements

No announcements available.

Key Stakeholders

Name	Title
Samsung C&T Corp.	Public Company
Samsung Electronics Co., Ltd.	Public Company
Dong-Joong Kim	Individual
James J. Choi	Individual
Sang-won Seo	Individual